{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Control+II&page=99", "query": { "intervention": "Control II", "page": 99 }, "page_size": 10 }, "pagination": { "page": 99, "page_size": 10, "total_count": 2671, "total_pages": 268, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Control+II&page=100&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Control+II&page=98&page_size=10" }, "source": "remote", "last_synced_at": "2026-11-04T15:09:28.332Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT01964235", "title": "Study of Efficacy and Safety INC280 in Patients With Advanced Hepatocellular Carcinoma", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Advanced Hepatocellular Carcinoma" ], "interventions": [ { "name": "INC280", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 0, "start_date": "2016-12", "completion_date": "2019-07", "has_results": false, "last_update_posted_date": "2016-09-01", "last_synced_at": "2026-11-04T15:09:28.332Z", "location_count": 2, "location_summary": "Boston, Massachusetts • Kansas City, Missouri", "locations": [ { "city": "Boston", "state": "Massachusetts" }, { "city": "Kansas City", "state": "Missouri" } ], "official_url": "https://clinicaltrials.gov/study/NCT01964235" }, { "nct_id": "NCT00475085", "title": "Prevention of Delayed Nausea A Phase III Double-Blind Placebo-Controlled Clinical Trial", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Nausea" ], "interventions": [ { "name": "aprepitant", "type": "DRUG" }, { "name": "dexamethasone", "type": "DRUG" }, { "name": "granisetron hydrochloride", "type": "DRUG" }, { "name": "palonosetron hydrochloride", "type": "DRUG" }, { "name": "prochlorperazine", "type": "DRUG" }, { "name": "placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Joseph Roscoe", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 1021, "start_date": "2006-12", "completion_date": null, "has_results": true, "last_update_posted_date": "2015-11-10", "last_synced_at": "2026-11-04T15:09:28.332Z", "location_count": 16, "location_summary": "Mobile, Alabama • Decatur, Illinois • Wichita, Kansas + 13 more", "locations": [ { "city": "Mobile", "state": "Alabama" }, { "city": "Decatur", "state": "Illinois" }, { "city": "Wichita", "state": "Kansas" }, { "city": "Grand Rapids", "state": "Michigan" }, { "city": "Kalamazoo", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT00475085" }, { "nct_id": "NCT04572815", "title": "Ustekinumab for the Prevention of Acute Graft-versus-Host Disease After Unrelated Donor Hematopoietic Cell Transplant", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Hematologic and Lymphocytic Disorder", "Hematopoietic and Lymphoid System Neoplasm" ], "interventions": [ { "name": "Placebo Administration", "type": "DRUG" }, { "name": "Quality-of-Life Assessment", "type": "OTHER" }, { "name": "Questionnaire Administration", "type": "OTHER" }, { "name": "Ustekinumab", "type": "BIOLOGICAL" } ], "intervention_types": [ "DRUG", "OTHER", "BIOLOGICAL" ], "sponsor": "Fred Hutchinson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 116, "start_date": "2021-05-14", "completion_date": "2027-06-30", "has_results": false, "last_update_posted_date": "2026-01-02", "last_synced_at": "2026-11-04T15:09:28.332Z", "location_count": 4, "location_summary": "Duarte, California • Tampa, Florida • Buffalo, New York + 1 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Tampa", "state": "Florida" }, { "city": "Buffalo", "state": "New York" }, { "city": "Seattle", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT04572815" }, { "nct_id": "NCT06650579", "title": "REVELUTION-2: Relugolix+Abiraterone Acetate (AA) Versus Leuprolide+AA Cardiac Trial", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Recurrent Prostate Carcinoma", "Stage III Prostate Cancer AJCC v8", "Stage IVA Prostate Cancer AJCC v8" ], "interventions": [ { "name": "Abiraterone Acetate", "type": "DRUG" }, { "name": "Bicalutamide", "type": "DRUG" }, { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Computed Tomography Angiography", "type": "PROCEDURE" }, { "name": "Leuprolide", "type": "DRUG" }, { "name": "Prednisone", "type": "DRUG" }, { "name": "Radiation Therapy", "type": "RADIATION" }, { "name": "Relugolix", "type": "DRUG" } ], "intervention_types": [ "DRUG", "PROCEDURE", "RADIATION" ], "sponsor": "Emory University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 72, "start_date": "2025-01-31", "completion_date": "2029-07-01", "has_results": false, "last_update_posted_date": "2026-02-24", "last_synced_at": "2026-11-04T15:09:28.332Z", "location_count": 4, "location_summary": "Atlanta, Georgia", "locations": [ { "city": "Atlanta", "state": "Georgia" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Atlanta", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT06650579" }, { "nct_id": "NCT00089180", "title": "T4N5 Liposomal Lotion in Preventing The Recurrence of Nonmelanoma Skin Cancer in Patients Who Have Undergone a Kidney Transplant", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Actinic Keratosis", "Basal Cell Carcinoma of the Skin", "Recurrent Skin Cancer", "Squamous Cell Carcinoma of the Skin" ], "interventions": [ { "name": "liposomal T4N5 lotion", "type": "DRUG" }, { "name": "placebo", "type": "OTHER" }, { "name": "laboratory biomarker analysis", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "19 Years", "maximum_age": null, "sex": "ALL", "summary": "19 Years and older" }, "enrollment_count": 100, "start_date": "2004-03", "completion_date": null, "has_results": false, "last_update_posted_date": "2015-12-04", "last_synced_at": "2026-11-04T15:09:28.332Z", "location_count": 1, "location_summary": "Birmingham, Alabama", "locations": [ { "city": "Birmingham", "state": "Alabama" } ], "official_url": "https://clinicaltrials.gov/study/NCT00089180" }, { "nct_id": "NCT00002160", "title": "A Multicenter Phase II/III, Placebo-Controlled Study of SNX-111 Administered Intrathecally to Cancer and AIDS Patients With Chronic Pain", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "HIV Infections", "Cancer", "Pain" ], "interventions": [ { "name": "Ziconotide", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Neurex", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 100, "start_date": null, "completion_date": null, "has_results": false, "last_update_posted_date": "2005-06-24", "last_synced_at": "2026-11-04T15:09:28.332Z", "location_count": 44, "location_summary": "Huntsville, Alabama • Mobile, Alabama • Northport, Alabama + 38 more", "locations": [ { "city": "Huntsville", "state": "Alabama" }, { "city": "Mobile", "state": "Alabama" }, { "city": "Northport", "state": "Alabama" }, { "city": "Fort Smith", "state": "Arkansas" }, { "city": "Berkeley", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00002160" }, { "nct_id": "NCT00516659", "title": "ETEC Logistics Trial (TREK)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Diarrhea" ], "interventions": [ { "name": "Heat-Labile Enterotoxin of Escherichia coli (LT)", "type": "BIOLOGICAL" }, { "name": "Placebo", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Intercell USA, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "64 Years", "sex": "ALL", "summary": "18 Years to 64 Years" }, "enrollment_count": 201, "start_date": "2006-05", "completion_date": "2007-12", "has_results": false, "last_update_posted_date": "2012-03-14", "last_synced_at": "2026-11-04T15:09:28.332Z", "location_count": 13, "location_summary": "Long Beach, California • Chicago, Illinois • Baltimore, Maryland + 9 more", "locations": [ { "city": "Long Beach", "state": "California" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "Minneapolis", "state": "Minnesota" }, { "city": "Hackensack", "state": "New Jersey" } ], "official_url": "https://clinicaltrials.gov/study/NCT00516659" }, { "nct_id": "NCT00524017", "title": "Cetuximab in Treating Patients With Precancerous Lesions of the Upper Aerodigestive Tract", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Head and Neck Cancer", "Precancerous Condition" ], "interventions": [ { "name": "cetuximab", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "120 Years", "sex": "ALL", "summary": "18 Years to 120 Years" }, "enrollment_count": 35, "start_date": "2007-05", "completion_date": "2011-12", "has_results": true, "last_update_posted_date": "2020-03-12", "last_synced_at": "2026-11-04T15:09:28.332Z", "location_count": 9, "location_summary": "San Francisco, California • Chicago, Illinois • Lexington, Kentucky + 5 more", "locations": [ { "city": "San Francisco", "state": "California" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Lexington", "state": "Kentucky" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT00524017" }, { "nct_id": "NCT04589650", "title": "Study Assessing the Efficacy, Safety and PK of Alpelisib (BYL719) in Pediatric and Adult Patients With PIK3CA-related Overgrowth Spectrum", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "PIK3CA-related Overgrowth Spectrum (PROS)" ], "interventions": [ { "name": "Alpelisib", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "0 Days", "maximum_age": "100 Years", "sex": "ALL", "summary": "0 Days to 100 Years" }, "enrollment_count": 236, "start_date": "2021-04-19", "completion_date": "2031-01-09", "has_results": true, "last_update_posted_date": "2026-10-07", "last_synced_at": "2026-11-04T15:09:28.332Z", "location_count": 11, "location_summary": "San Francisco, California • Aurora, Colorado • St Louis, Missouri + 7 more", "locations": [ { "city": "San Francisco", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "St Louis", "state": "Missouri" }, { "city": "New York", "state": "New York" }, { "city": "Chapel Hill", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT04589650" }, { "nct_id": "NCT01643850", "title": "MCS110 in Patients With Pigmented Villonodular Synovitis (PVNS)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Pigmented Villonodular Synovitis", "PVNS", "Giant Cell Tumor of the Tendon Sheath", "GCCTS", "Tenosynovial Giant Cell Tumor Localized or Diffused Type", "GCTS" ], "interventions": [ { "name": "MCS110", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Years", "maximum_age": null, "sex": "ALL", "summary": "12 Years and older" }, "enrollment_count": 36, "start_date": "2012-04-23", "completion_date": "2018-12-21", "has_results": true, "last_update_posted_date": "2021-01-05", "last_synced_at": "2026-11-04T15:09:28.332Z", "location_count": 7, "location_summary": "San Diego, California • Denver, Colorado • Washington D.C., District of Columbia + 4 more", "locations": [ { "city": "San Diego", "state": "California" }, { "city": "Denver", "state": "Colorado" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Miami", "state": "Florida" }, { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT01643850" } ] }